Context Therapeutics's quarterly market cap
increased
from Mar. 2024 ($22.03 Mil) to Jun. 2024 ($150.37 Mil) but then
declined
from Jun. 2024 ($150.37 Mil) to Sep. 2024 ($147.00 Mil).
Context Therapeutics's annual market cap
declined
from Dec. 2021 ($42.47 Mil) to Dec. 2022 ($10.41 Mil) but then
increased
from Dec. 2022 ($10.41 Mil) to Dec. 2023 ($18.04 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Context Therapeutics's Enterprise Value for Today is $27.94 Mil.
Context Therapeutics Market Cap Historical Data
The historical data trend for Context Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Context Therapeutics's Market Cap
For the Biotechnology subindustry, Context Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Context Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Context Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Context Therapeutics's Market Cap falls into.
Context Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Context Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Context Therapeutics (NAS:CNTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Context Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Context Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CNTX has been successfully added to your 